Related references
Note: Only part of the references are listed.Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
Amr Menshawy et al.
MELANOMA RESEARCH (2018)
Talimogene laherparepvec: First in class oncolytic virotherapy
Robert M. Conry et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
Lillian Sun et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4
Xuan Mo et al.
CANCER RESEARCH (2018)
Virotherapy Research in Germany: From Engineering to Translation
Guy Ungerechts et al.
HUMAN GENE THERAPY (2017)
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
Karsten Geletneky et al.
MOLECULAR THERAPY (2017)
Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
Assia L. Angelova et al.
VIRUSES-BASEL (2017)
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
B. Heinrich et al.
ONCOTARGETS AND THERAPY (2017)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
Oncolytic Virus Immunotherapy for Melanoma
Neal Dharmadhikari et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Anna Sledzinska et al.
MOLECULAR ONCOLOGY (2015)
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
Youra Kim et al.
VIRUSES-BASEL (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Immune checkpoint inhibitors: therapeutic advances in melanoma
Ivan Marquez-Rodas et al.
ANNALS OF TRANSLATIONAL MEDICINE (2015)
Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer
Assia L. Angelova et al.
JOURNAL OF VIROLOGY (2014)
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1
Markus Moehler et al.
FRONTIERS IN ONCOLOGY (2014)
Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1
Maike Sieben et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
Stefania Laurent et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells
Bernd Heinrich et al.
ONCOTARGETS AND THERAPY (2013)
Cellular Constituents of Immune Escape within the Tumor Microenvironment
Sid P. Kerkar et al.
CANCER RESEARCH (2012)
Activation of a Helper and Not Regulatory Human CD4+T Cell Response by Oncolytic H-1 Parvovirus
Olivier Morales et al.
PLOS ONE (2012)
Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1
Markus Moehler et al.
BMC CANCER (2011)
CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions
Stefania Laurent et al.
HUMAN IMMUNOLOGY (2010)
Dendritic Cells Induce Regulatory T Cell Proliferation through Antigen-Dependent and -Independent Interactions
Tao Zou et al.
JOURNAL OF IMMUNOLOGY (2010)
Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV
Assia L. Angelova et al.
CLINICAL CANCER RESEARCH (2009)
CTLA-4 trafficking and surface expression
Elke Valk et al.
TRENDS IN IMMUNOLOGY (2008)
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
E Contardi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
V Lennerz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells
MH Moehler et al.
HUMAN GENE THERAPY (2005)
New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population
I Jedema et al.
BLOOD (2004)
Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells
M Moehler et al.
CANCER GENE THERAPY (2003)
Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors
M Moehler et al.
CANCER GENE THERAPY (2001)
Share Paper
